Nicotine Pouch Debate Heats Up: FDA Delays Raise Concerns

Nicotine pouches, which are often pitched as a less harmful alternative to smoking, have hit a hurdle with the U.S. Food and Drug Administration. Agency scientists are hesitating to authorize these products, citing potential risks to new users, especially children, three sources told Reuters.

Tobacco behemoths like Philip Morris International and British American Tobacco, who have invested heavily in these products, are facing setbacks as the FDA's fast-track program for approval remains stalled. The agency has raised specific concerns regarding risks to youth, evaluating if potential benefits for smokers outweigh these risks.

While nicotine pouches are deemed less harmful than traditional cigarettes, the FDA's cautious approach reflects significant worries about rising use among non-smokers and youth. The delay in approvals affects market players and highlights ongoing debates about public health and smoking alternatives.